Any progress in the clinical trial schedule should be beneficial. There is strength in the markets where there is demand for the drug and it's not directly in the international trade crossfire.
Not allowed to mention the name of the company under IHub TOS, but they put another 9 million shares on the market at $28 today and the share price, rather than dropping from $30 to $28, closed up slightly. This is in TODAYs market. There clearly is demand for their recently approved products and demand for the stock. Of course it is no longer pre-revenue, like BIVI.
News 
Market Data 
Discover 
